April 27 2023
The patient-reported outcomes (PROs) of the phase 3 NRG Oncology clinical trial RTOG 0815 comparing dose-escalated radiotherapy (RT) alone to dose-escalated RT combined with short-term (6 months) androgen deprivation therapy (STAD) indicate that the addition of STAD did not significantly impact urinary or bowel quality of life but did significantly decrease hormone and sexual quality of life. However, this decline in quality of life was temporary and there were no clinically meaningful differences in quality of life between treatment arms by one year after the initiation of treatment. These results were recently published in the Journal of Clinical Oncology.
This study recently reported results that were also published in the Journal of Clinical Oncology which indicated that the experimental treatment arm of dose-escalated RT with the STAD did not improve overall survival outcomes for men with intermediate-risk prostate cancer as initially hypothesized but, the use of STAD did improve other clinical outcomes such as rates of biochemical failure, distant metastases, and prostate cancer-specific mortality.
NRG-RTOG 0815 accrued 1,492 patients with intermediate risk prostate cancer and randomly assigned patients to receive either dose-escalated RT alone (external beam RT to 79.2 Gy, or external beam to 45 Gy with brachytherapy boost) or dose-escalated RT with 6 months of STAD with LHRH agonist/antagonist therapy plus anti-androgen. 420 patients agreed to participate in the quality of life component of the trial. Primary PRO in this analysis was measured by the Expanded Prostate Cancer Index Composite (EPIC) which is comprised of four individually validated domains: urinary, bowel, sexual, and hormonal domain scores. Secondary PROs were measured using the Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue short form. The Godin Leisure-Time Exercise Questionnaire (GTLTEQ), the Pittsburgh Sleep Quality Index (PSQI), and the EQ-5D self-assessment were also used to assess PROs. Assessments were performed at the end of RT, and at months 6, 12, and 60.
The primary PRO completion rates using EPIC were excellent at greater than or equal to 86% through the first year of follow-up, then 70-75% at 5 years. There were significant clinically meaningful (p<0.0001) deficits in the EPIC hormonal and sexual domains in Arm 2, combining dose-escalated RT with STAD at completion of RT and the 6-month follow-up. However, at one year, there were no significant clinically meaningful differences between arms and at the 5-year follow-up, the scores for both EPIC domains returned to baseline. There were also no significant clinically meaningful differences at any time points between arms for PROMIS-fatigue, EQ5D, and EPIC bowel or urinary scores.
“While there is an initial decline in the hormone and sexual quality of life for men that received short term hormones in addition to radiation, it is reassuring that this impact was temporary and that quality-of-life outcomes were not clinically meaningfully different between arms by one year,” stated Benjamin Movsas, MD, Medical Director of the Henry Ford Health Cancer and the lead author of the NRG-RTOG 0815 PROs publication. “Patient-reported outcomes such as these are incredibly valuable to help individuals make informed decisions when determining their treatment options. We are particularly pleased that the clinical outcomes paper and the patient reported outcomes paper for NRG RTOG 0815 were published in the same issue of the Journal of Clinical Oncology, as together they tell the ‘whole story’ for this important clinical setting.”
Supported by grants UG1CA189867 (NCORP), U10CA180868 (NRG Operations), U24CA180803 (IROC), and U10CA180822 (SDMC) from the National Cancer Institute (NCI).
Movsas B, Rodgers JP, Elshaikh MA, Martinez AA, Morton GC, Krauss DJ, Yan D, Citrin DE, Hershatter BW, Michalski JM, Ellis RJ, Kavadi VS, Gore EM, Gustafson GS, Schulz CA, Velker VM, Olson AC, Cury FL, Papagikos MA, Karrison TG, Sandler HM, Bruner DW. Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial. J Clin Oncol. 2023 Apr 27:JCO2202389. doi: 10.1200/JCO.22.02389. Epub ahead of print. PMID: 37104723.
About NRG Oncology
NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the legacy National Surgical Adjuvant Breast and Bowel Project (NSABP), Radiation Therapy Oncology Group (RTOG), and Gynecologic Oncology Group (GOG) programs. The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.